Impact of Alemtuzumab on Health-Related Quality of Life Over 6 Years in CARE-MS II Trial Extension Patients With Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis - United States
doi 10.1177/1352458519849796
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 30, 2019
Authors
Publisher
SAGE Publications